Case ReportsLurasidone in first-episode psychosis with predominant depressive symptoms: a case reportRicci, Valerioa; Di Salvo, Gabrieleb; Maina, Giuseppeb Author Information aDepartment of Psychiatry, San Luigi Gonzaga University Hospital, Regione Gonzole, Orbassano bRita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy Received 13 December 2022 Accepted 6 February 2023. Correspondence to Valerio Ricci, MD, PhD, Department of Psychiatry, San Luigi Gonzaga University Hospital, Regione Gonzole, 10, Orbassano, Turin 10043, Italy, Tel: +39 3929659725; e-mail: [email protected] International Clinical Psychopharmacology 38(4):p 275-280, July 2023. | DOI: 10.1097/YIC.0000000000000465 Buy Metrics Abstract Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have an antidepressant effect due to 5-HT7 as well as 5-HT2A and 5-HT1a receptor affinity. Here we present a case of a 19-year-old male patient with first-episode psychosis (FEP) and predominant depressive symptoms. Remarkable clinical and functional improvement was observed 3 months after the beginning of lurasidone treatment. The patient’s depressive symptoms disappear with a dramatic reduction of psychotic ones, with good tolerance of the drug and without adverse effects. Lurasidone seems to be a promising treatment option for FEP with predominant depressive symptoms. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.